Bladder & Urothelial Cancer Excellence Forum

Bladder & Urothelial Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center

The Importance of a Multidisciplinary Approach to Bladder Cancer

11/23/2021

Petros Grivas, explains the importance of a multidisciplinary tumor board when reviewing the treatment options for patients with bladder cancer.

Petros Grivas, explains the...

11/23/2021

Oncology

Podcasts

Dr Williams Reviews SunRISe-2 Trial Results for Muscle-Invasive Urothelial Carcinoma

11/22/2021

Stephen Williams, MD, MS, FACS, discusses the SunRISe-2 trial evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in patients with muscle-invasive urothelial carcinoma.

Stephen Williams, MD, MS, FACS,...

11/22/2021

Oncology

Videos

Avelumab-Based Neoadjuvant Chemotherapy for Patients With Non–Metastatic, Muscle-Invasive Bladder Cancer: AURA Trial

11/11/2021

Nieves Martínez Chanzá, MD, PhD, discusses the AURA trial evaluating avelumab as the basis of neoadjuvant chemotherapy in platinum-eligible and ineligible patients with non-metastatic muscle-invasive bladder cancer.

Nieves Martínez Chanzá, MD, PhD,...

11/11/2021

Oncology

Videos

Dr Powles Reviews NORSE Study Results in FGFR3, FGFR2 Genetically Altered mUC

10/27/2021

Thomas Powles, MRCP, MD, discusses evaluating erdafitinib in combination with cetrelimab in patients with locally advanced or mUC with FGFR3 or FGFR2 genetic alterations ineligible for cisplatin.

Thomas Powles, MRCP, MD,...

10/27/2021

Oncology

Videos

Dr Lee Highlights Results of Nivolumab Plus Cabozantinib in Non-Clear Cell Kidney Cancer

07/01/2021

Chung-Han Lee, MD, Memorial Sloan Kettering Cancer Center, highlights the phase 2 clinical trial results of nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma, presented at the 2021 ASCO Annual Meeting.

Chung-Han Lee, MD, Memorial...

07/01/2021

Oncology

Videos

Dr Grivas Discusses Updates from the JAVELIN Bladder 100 Trial

06/29/2021

Petros Grivas, MD, PhD, highlights updates from the phase III JAVELIN Bladder 100 trial for advanced urothelial carcinoma.

Petros Grivas, MD, PhD,...

06/29/2021

Oncology

Videos

Dr Grivas Discusses Trial Results of Nivolumab or Lirilumab for MIBC

06/27/2021

Petros Grivas, MD, PhD, discusses phase Ib trial results of neoadjuvant nivolumab or lirilumab for cisplatin-ineligible patients with MIBC.

Petros Grivas, MD, PhD,...

06/27/2021

Oncology

Videos

Dr Choueiri Highlights Nivolumab Plus Cabozantinib vs Sunitinib for Advanced RCC

02/16/2021

Toni Choueiri, MD, shares results from a new analysis of the phase 3 Checkmate 9ER trial of cabozantinib plus nivolumab for the first-line treatment of advanced RCC.

Toni Choueiri, MD, shares...

02/16/2021

Oncology

Podcasts

No DFS Benefit With Adjuvant Atezolizumab for High-Risk Urothelial Carcinoma

02/12/2021

Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.

Petros Grivas, MD, PhD, talks...

02/12/2021

Oncology

News

Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer

07/27/2020

Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.

Pembrolizumab was active in...

07/27/2020

Oncology

Recent News

News

Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer

07/27/2020

Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.

Pembrolizumab was active in...

07/27/2020

Oncology

News

Switch Maintenance Pembrolizumab Improves Response, PFS in Metastatic Urothelial Cancer

05/01/2020

Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.

Switch maintenance pembrolizumab...

05/01/2020

Oncology

News

Enfortumab Vedotin Monotherapy Yields Durable Responses in Metastatic Urothelial Cancer

02/26/2020

Enfortumab vedotin monotherapy has demonstrated meaningful and durable responses in patients with metastatic urothelial cancer.

Enfortumab vedotin monotherapy...

02/26/2020

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology